Details of the Drug Reposition

General Information of This Drug (ID: DMQ1Q37)

Drug Name
Megesterol acetate   DMQ1Q37

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Atypical endometrial hyperplasia DIS2POYG N.A. Approved [1]
Breast cancer DIS7DPX1 2C60-2C65 Approved [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Endometrium adenocarcinoma DISY6744 N.A. Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Endometrial carcinoma DISXR5CY N.A. Investigative [4]
------------------------------------------------------------------------------------

References

1 Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med. 2021 Feb;112(1):55-69.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
4 Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis. Exp Biol Med (Maywood). 2021 Nov;246(21):2307-2316.